"Today represents the first real acknowledgement that team and those scientists have gotten that their technology was instrumental in Covid-19 vaccines, or at least the Moderna vaccine as we're announcing today with this settlement. This settlement validates the scientific contributions made by the researchers at Arbutus and Genevant in developing the lipid nanoparticle delivery system."
"The patent dispute focused on lipid nanoparticles (LNPs), tiny fat particles that encapsulate mRNA and protect it during its journey through the body to its cellular destination. Moderna's mRNA vaccine for Covid-19 uses LNPs for delivery. In a joint complaint filed in 2022, Arbutus and Genevant contended this vaccine infringed their LNP delivery patents."
"Moderna contended its Covid-19 vaccine did not infringe any valid patents. But its defense focused on another argument: Arbutus and Genevant sued the wrong party. Moderna had said the companies should instead sue the U.S. government because the Covid-19 vaccine that became Spikevax was developed and brought to the market under a federal contract."
Moderna has agreed to settle a patent dispute with Arbutus Biopharma and Genevant Sciences over lipid nanoparticle (LNP) technology used in mRNA Covid-19 vaccines. The settlement includes $950 million upfront and potentially over $1 billion in additional payments. The dispute centered on whether Moderna's Covid-19 vaccine infringed LNP delivery patents held by Arbutus and Genevant. Moderna had argued the companies should sue the U.S. government instead, citing Section 1498 of the U.S. Code, which shields government contractors from patent claims. The settlement comes days before trial was set to begin and represents recognition of the scientists' contributions to vaccine technology development.
#patent-dispute-settlement #lipid-nanoparticle-technology #mrna-covid-19-vaccines #moderna-licensing
Read at MedCity News
Unable to calculate read time
Collection
[
|
...
]